Michele R Wilson1, Annika Bergman2, Helene Chevrou-Severac2, Ross Selby3, Michael Smyth4, Matthew C Kerrigan5. 1. RTI Health Solutions, 300 Park Offices Drive, Research Triangle Park, NC, 27709, USA. mwilson@rti.org. 2. Takeda Pharmaceuticals AG, Zurich, Switzerland. 3. Takeda UK Ltd., Bucks, UK. 4. Takeda Development Centre Europe Ltd., London, UK. 5. PHMR Limited, London, UK.
Abstract
OBJECTIVE: To examine the clinical and economic impact of vedolizumab compared with infliximab, adalimumab, and golimumab in the treatment of moderately to severely active ulcerative colitis (UC) in the United Kingdom (UK). METHODS: A decision analytic model in Microsoft Excel was used to compare vedolizumab with other biologic treatments (infliximab, adalimumab, and golimumab) for the treatment of biologic-naïve patients with UC in the UK. Efficacy data were obtained from a network meta-analysis using placebo as the common comparator. Other inputs (e.g., unit costs, adverse-event disutilities, probability of surgery, mortality) were obtained from published literature. Costs were presented in 2012/2013 British pounds. Outcomes included quality-adjusted life-years (QALYs). Costs and outcomes were discounted by 3.5% per year. Incremental cost-effectiveness ratios were presented for vedolizumab compared with other biologics. Univariate and multivariate probabilistic sensitivity analyses were conducted to assess model robustness to parameter uncertainty. RESULTS: The model predicted that anti-tumour necrosis factor-naïve patients on vedolizumab would accrue more QALY than patients on other biologics. The incremental results suggest that vedolizumab is a cost-effective treatment compared with adalimumab (incremental cost-effectiveness ratio of £22,735/QALY) and dominant compared with infliximab and golimumab. Sensitivity analyses suggest that results are most sensitive to treatment response and transition probabilities. However, vedolizumab is cost-effective irrespective of variation in any of the input parameters. CONCLUSIONS: Our model predicted that treatment with vedolizumab improves QALY, increases time in remission and response, and is a cost-effective treatment option compared with all other biologics for biologic-naïve patients with moderately to severely active UC.
OBJECTIVE: To examine the clinical and economic impact of vedolizumab compared with infliximab, adalimumab, and golimumab in the treatment of moderately to severely active ulcerative colitis (UC) in the United Kingdom (UK). METHODS: A decision analytic model in Microsoft Excel was used to compare vedolizumab with other biologic treatments (infliximab, adalimumab, and golimumab) for the treatment of biologic-naïve patients with UC in the UK. Efficacy data were obtained from a network meta-analysis using placebo as the common comparator. Other inputs (e.g., unit costs, adverse-event disutilities, probability of surgery, mortality) were obtained from published literature. Costs were presented in 2012/2013 British pounds. Outcomes included quality-adjusted life-years (QALYs). Costs and outcomes were discounted by 3.5% per year. Incremental cost-effectiveness ratios were presented for vedolizumab compared with other biologics. Univariate and multivariate probabilistic sensitivity analyses were conducted to assess model robustness to parameter uncertainty. RESULTS: The model predicted that anti-tumour necrosis factor-naïve patients on vedolizumab would accrue more QALY than patients on other biologics. The incremental results suggest that vedolizumab is a cost-effective treatment compared with adalimumab (incremental cost-effectiveness ratio of £22,735/QALY) and dominant compared with infliximab and golimumab. Sensitivity analyses suggest that results are most sensitive to treatment response and transition probabilities. However, vedolizumab is cost-effective irrespective of variation in any of the input parameters. CONCLUSIONS: Our model predicted that treatment with vedolizumab improves QALY, increases time in remission and response, and is a cost-effective treatment option compared with all other biologics for biologic-naïve patients with moderately to severely active UC.
Authors: Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar Journal: Gut Date: 2011-01-05 Impact factor: 23.059
Authors: David T Rubin; Marla C Dubinsky; Remo Panaccione; Corey A Siegel; David G Binion; Sunanda V Kane; Joseph Hopper Journal: Dig Dis Sci Date: 2009-09-04 Impact factor: 3.199
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Toshifumi Hibi; Paul Rutgeerts Journal: Gastroenterology Date: 2013-06-02 Impact factor: 22.682
Authors: K M Beusterien; S M Szabo; S Kotapati; J Mukherjee; A Hoos; P Hersey; M R Middleton; A R Levy Journal: Br J Cancer Date: 2009-07-14 Impact factor: 7.640
Authors: Charles Miller; Hanson Kwok; Paul Harrow; Roser Vega; Edward Seward; Shameer Mehta; Farooq Rahman; Sara McCartney; Ioanna Parisi; Samuel Hsiang Lim; Esha Sharma; Mark A Samaan; Aaron Bancil; Klaartje Bel Kok; Ahmed Shalabi; Emma L Johnston; Dev Katarey; Nina Taherzadeh; Charles Murray; Mohammed Tauseef Sharip; Martyn J Carter; Shiva T Radhakrishnan; Simon Peake; Imran Khakoo; Mahmood Wahed; Sebastian Povlsen; Mehul Patel; Patrick DuBois; Jemima Finkel; Clive Onnie; Stuart Bloom Journal: Frontline Gastroenterol Date: 2022-01-07
Authors: Michele R Wilson; Ismail Azzabi Zouraq; Helene Chevrou-Severac; Ross Selby; Matthew C Kerrigan Journal: Clinicoecon Outcomes Res Date: 2017-10-16